Literature DB >> 30145635

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Evangelia Zampeli1, Aliki Venetsanopoulou2, Ourania D Argyropoulou2, Clio P Mavragani2,3, Maria G Tektonidou4, Panayiotis G Vlachoyiannopoulos2, Athanasios G Tzioufas2, Fotini N Skopouli5, Haralampos M Moutsopoulos6,2,7.   

Abstract

Myositis-specific (MSAs) or-associated autoantibodies (MAAs) have been linked to particular clinical phenotypes of idiopathic inflammatory myopathies (IIM) and appear to aid diagnosis. The objective of this study was to analyze the prevalence of MSAs and MAAs and their possible clinical associations in Greek IIM patients. This study comprised 95 IIM patients classified based on the 2017 EULAR/ACR classification criteria. All patients had MSAs and MAAs measured in their sera by line immunoblot assay. Dermatomyositis was the most prevalent IIM clinical subtype. MSAs were found in 44% of the patients, whereas MAAs in 23%. The most frequently detected MSA was anti-Jo-1 (22%), while the most frequently detected MAA was anti-Ro-52 (30%). The distributions of MSAs/MAAs did not differ between the five IIM subgroups, except for anti-Mi-2 which was only detected in dermatomyositis patients. Patients with at least one MSA and/or MAA positivity showed more frequently IIM characteristic skin rashes, while those presenting solely MAA positivity had more often puffy hands and Raynaud's phenomenon. Anti-Jo1-positive patients presented more frequently lung disease, while anti-Ro52 positivity related to mechanic's hands. Anti-Ro-52 and anti-Jo-1 strongly associated with one another. Prevalence of IIM subtypes and of MSAs/MAAs in our patients is in line with published reports in populations of similar geographic distribution. While MSA and/or MAA positivity did associate with particular clinical manifestations, it did not predict in our cohort specific IIM subgroup as defined by the latest EULAR/ACR classification criteria. Future studies are warranted to conclusively decide if these autoantibodies, measured with a standardized method, should or not be incorporated in every day clinical practice to aid IIM diagnosis.

Entities:  

Keywords:  Dermatomyositis; Idiopathic inflammatory myopathies; Myositis-associated autoantibodies; Myositis-specific autoantibodies; Polymyositis

Mesh:

Substances:

Year:  2018        PMID: 30145635     DOI: 10.1007/s10067-018-4267-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Lesson of the month 2: Fever, arthralgias and hyperkeratotic, scaling and fissuring eruptions of the hands.

Authors:  Evangelia Zampeli; Haralampos M Moutsopoulos
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

2.  The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.

Authors:  Shanshan Li; Yongpeng Ge; Hanbo Yang; Tao Wang; Xiaoxiao Zheng; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2019-03-12       Impact factor: 2.980

Review 3.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

4.  Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study.

Authors:  Federica Montagnese; Haris Babačić; Peter Eichhorn; Benedikt Schoser
Journal:  J Neurol       Date:  2019-03-06       Impact factor: 4.849

5.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

6.  A North American Cohort of Anti-SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases.

Authors:  Jemima Albayda; Christopher Mecoli; Livia Casciola-Rosen; Sonye K Danoff; Cheng Ting Lin; David Hines; Laura Gutierrez-Alamillo; Julie J Paik; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine
Journal:  ACR Open Rheumatol       Date:  2021-03-28

7.  Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.

Authors:  Andrés Hormaza-Jaramillo; Vanessa Bedoya-Joaqui; Germán Puerta-Sarmiento; Mario Bautista; Lady J Rios-Serna; Tatiana Delgado-Mora; Ivana Nieto-Aristizábal; Ingrid Ruiz-Ordoñez
Journal:  Front Med (Lausanne)       Date:  2022-08-15

8.  The Association of Myositis Specific Antibodies in Patients with Inflammatory Myositis: Preliminary Data in Indian Patients.

Authors:  Natasha Vijay Negalur; Gayatri G Ekbote; Dhiren N Raval; Dhaval V Tanna; Wasim S Kazi; Muzaffar A Bindroo; Durgarao J Yadavalli; Rajiva Gupta
Journal:  Ann Indian Acad Neurol       Date:  2021-05-21       Impact factor: 1.383

9.  Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study.

Authors:  Shamma Ahmad Al Nokhatha; Eman Alfares; Luke Corcoran; Niall Conlon; Richard Conway
Journal:  Rheumatol Int       Date:  2021-10-04       Impact factor: 2.631

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.